X
OCUL icon

Xponance’s Ocular Therapeutix OCUL Stock Holding History

Xponance’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Buy
17,107
+2,473
+17% +$23.6K ﹤0.01% 1524
2025
Q4 		$178K Buy
14,634
+3,679
+34% +$44.7K ﹤0.01% 1409
2025
Q3 		$128K Buy
10,955
+89
+0.8% +$1.06K ﹤0.01% 1419
2025
Q2 		$101K Sell
10,866
-969
-8% -$7.58K ﹤0.01% 1410
2025
Q1 		$86.8K Buy
11,835
+754
+7% +$5.79K ﹤0.01% 1361
2024
Q4 		$94.6K Buy
11,081
+812
+8% +$7.92K ﹤0.01% 1372
2024
Q3 		$89.3K Buy
+10,269
New +$84.6K ﹤0.01% 1327

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Xponance's OCUL Position: Q1 2026 in Review

Xponance increased its Ocular Therapeutix (OCUL) stake by 17% in Q1 2026, buying an estimated $23.6K and bringing the position to 17,107 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

Xponance first reported a position in OCUL in Q3 2024 and has held it in 7 quarters since. The position peaked at $178K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Xponance held 17,107 shares of Ocular Therapeutix worth $145K as of Q1 2026.
  • Xponance bought 2,473 Ocular Therapeutix shares in Q1 2026, an estimated $23.6K.
  • Ocular Therapeutix made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1524 holding.
  • Xponance first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 7 quarters since.
  • Xponance's Ocular Therapeutix position peaked at $178K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.